Craig-Hallum raised the firm’s price target on Eton Pharmaceuticals (ETON) to $28 from $26 and keeps a Buy rating on the shares following Q1 earnings, which was another strong performance. The company reiterated an $80M run-rate goal by year-end, though the firm sees this as conservative based on current trends and has modeled slightly above this level.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ETON: